Find the Right Bile Duct Cancer (Cholangiocarcinoma) Clinical Trial
- There are hundreds of clinical trials that are actively recruiting for cholangiocarcinoma worldwide.
- Fill the form to get your personalized cholangiocarcinoma clinical trial matching options.
Rapid and High-Quality Clinical Trial Options
Massive Bio’s Clinical Trial Matching System can quickly and efficiently prescreen you for cholangiocarcinoma clinical trials. Your personalized trial options are under the supervision of clinical experts from more than two dozen National Cancer Institute (NCI) designated cancer centers. Navigating through the 30,000 clinical trials available in the United States is difficult to do on your own, we can help find the best mach for you.
Case Management Team Resolving Enrollment Issues
Just identifying a clinical trial does not mean you will be enrolled. 75% of the time, patients are not enrolled to a clinical trial due to last minute issues. Pre-screening our patients for Cholangiocarcinoma clinical trial matches eliminates those last-minute enrollment issues. Thus, Massive Bio’s experienced case management team helps you during site selection, escalation of financial issues to the study Sponsor and/or other matters that may limit your enrollment.
No Need to Travel Until You Decide on A Trial
When you are working with Massive Bio, you know whether you are eligible or not for a specific clinical trial before you start the enrollment process. This is extremely important because more than 65% of the time you may not be eligible to a trial and you would not be informed until travelling all the way to the site. Massive Bio is able to inform you about your screening results before you even go to the site, allowing you to be pre-screened for multiple trials at once.
What is Cholangiocarcinoma?
Cholangiocarcinoma or Bile Duct Cancer is a rare malignancy arising from the epithelial cells within the liver (intrahepatic and extrahepatic bile ducts), which can only be cured after multidisciplinary treatment and complete surgical resection (removed). If surgery is not possible due to metastatic disease (spread outside the liver), patients may benefit from systemic therapy, including chemotherapy and clinical trials, aiming to prolong progression-free and overall survival. These treatments also improve disease-related symptoms (relief of pain, jaundice, and bowel obstruction) and quality of life.
Patients with intrahepatic cholangiocarcinoma (tumor is inside the liver) may harbor mutations within their cancer that drive the tumor growth, and can be targeted with personalized treatments known as tyrosine kinase inhibitors (a form of targeted therapy). Those mutations are detected by performing specialized tests such as genomic testing. Among those alterations are FGFR, BRAF, MSI-high, NTRK, ERBB2 (Her-2) and high Tumor Mutational Burden (TMB).